Jon joined FLG in 2004 and is an experienced financial executive with more than 45 years’ experience in finance and operations. His expertise ranges from raising equity and debt in both public and private markets, to building financial reporting and control systems, resolving complex accounting, and reporting issues, managing and integrating acquisitions and managing high-growth organizations.
Jon currently serves as Chief Financial Officer of Kyverna Therapeutics, Inc., a pre-clinical stage private company focused on synthetic biology, immunology, and cell engineering to create a new class of T-cell therapies programmed to target and selectively modulate the underlying causes of autoimmunity. Additionally, Jon is currently advising a public life sciences company and a private Saas-based technology company regarding technical accounting, reporting and audit-related matters.
Jon most recently served as Chief Financial Officer of SmartRent, Inc. (NYSE: SMRT) and Vera Therapeutics, Inc. (Nasdaq: VERA). SmartRent successfully completed its SPAC merger with Fifth Wall Acquisition Corp. in August 2021 under Jon’s leadership. SmartRent is an enterprise smart home automation company developing, installing, and servicing software and hardware that enables property owners, managers, and homebuilders to seamlessly manage, protect and automate daily operational processes for continued security and comfort. Vera Therapeutics successfully completed its IPO in May 2021 under Jon’s leadership. Vera Therapeutics is developing multiple novel biologic molecules to improve the standard of care for patients with immunologic diseases. Immediately prior to his work with SmartRent and Vera Therapeutics, Jon was engaged as Interim Chief Financial Officer for Amyris, Inc. (Nasdaq: AMRS), an industrial biotechnology company. Jon was engaged after Amyris determined to restate its annual financial statements for 2017 and quarterly financial statement for 2018, which restatement caused a significant delay to the Company’s timely SEC filings and resulted in NASDAQ notifying the Company of de-listing. Jon led the effort to successfully complete the audits and related filings prior to Nasdaq’s de-listing deadline. Prior to Amyris, Jon was engaged as Chief Financial Officer of Soleno Therapeutics, Inc. (NASDAQ: SLNO), which is performing Phase III human trials for the use of DCCR for the orphan indication of Prader-Willi Syndrome and of Verana Health, Inc., a private, venture backed firm that partners with medical associations to assemble the largest clinical databases in medicine.
Prior to these engagements, Jon served as Vice President and Chief Financial Officer of PARC (Palo Alto Research Center, Inc.) a Xerox company. Initially engaged by PARC on a consulting engagement to assist with several operational projects, Jon was asked to join PARC as CFO.
Jon’s previous client engagements include: assisting a $14 billion national bank restate its previously-issued financial statements; assisting Tom Sawyer Software with securing construction and permanent financing for its operating facilities; assisting a private, venture-backed software consulting firm with the integration of European acquisitions and with establishing US-GAAP based financial reporting policies across its international operations; and, engagement as Vice President and Chief Financial Officer of Neurobiological Technologies, Inc. (NASDAQ: NTII), a biotechnology firm. Before his engagement with NTII, Jon was the consulting CFO for a public, natural resources company and managed a consulting engagement for the initial Sarbanes-Oxley controls examination of SanDisk Corporation (Nasdaq: SNDK), a multi-billion-dollar supplier of memory devices.
Before starting his consulting career, Jon: served as CFO for Latin American operations and International Controller with KPMG Consulting, for whom he managed the acquisition and integration of 11 international consulting practices and managed financial reporting, financial planning and cash forecasting throughout 26 countries in the Latin America and Asia-Pacific regions; served as Corporate Controller at Exponent (formerly Failure Analysis Associates); and, served as Treasurer of First Republic Bank. Jon started his career at Arthur Andersen & Co. in San Francisco where he practiced in the audit division for 11 years.
Jonathan's Perspective on FLG
I am gratified when our clients tell us that we are the best in class resource for providing guidance and helping solve their challenging problems. Our partners are deeply experienced and we bring a sense of urgency to each client engagement. I am proud to be a partner amongst peers who focus on delivering consistent, solid value to our clients.- Jonathan Wolter
- Life Sciences
- Professional Services
- Financial Services